Localized Renal Cell Carcinoma
Advertisement
Tumor grade, sarcomatoid features may influence outcomes with adjuvant nivo/ipi in patients with RCC after nephrectomy.
Partial nephrectomy has been gaining traction as an effective treatment for RCC due to its safety and efficacy.
Tumors with only a VHL mutation were associated with better outcomes compared with tumors containing additional mutations.
AUA guidelines for localized RCC have thermal ablation as an alternative modality. EAU guidelines are conflicting.
SAbR could potentially serve as a new noninvasive alternative treatment, but data on the procedure are limited.
A review of adjuvant therapies shows patient characteristics that may result in favorable treatment responses.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
Researchers presented the largest retrospective characterization of localized RCC with sarcomatoid dedifferentiation.
Matthew Zibelman, MD, highlights SOC adjuvant therapy for localized RCC and practice-changing potential of novel therapies.
A new study evaluated renal function outcomes for patients with oncocytoma managed with surveillance vs nephrectomy.
Guadecitabine may be well tolerated in patients with dSDH tumors, including HLRCC-RCC, according to results of a new study.
Cryoablation and heat-based thermal ablation represent alternative management options for frail and/or comorbid RCC patients.
Stereotactic body radiotherapy can benefit RCC patients deemed unfit for surgical therapy.
Checkmate 914 assigned patients to nivolumab plus ipilimumab or placebo and found no difference in disease-free survival.
Researchers evaluated the new AUA risk stratification system for survival in patients with clear cell or papillary RCC.
There is little to no clinical value in surveillance of pulmonary recurrence following resection of T1a renal cell carcinoma.
Advertisement
670 Madison Ave.
Manalapan, NJ 07726